|
@frankvinluan | |||||
|
This @AcceleronPharma drug didn't pan out treating a rare blood disorder or chronic kidney disease. But with positive topline Phs 2 data in #pulmonaryarterialhypertension, some now see blockbuster potential. $XLRN shares shot up 50% Tues. xconomy.com/boston/2020/01… #PAH
|
||||||
|
||||||